quinazolines has been researched along with Mastitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Fu, S; Guo, W; Hou, S; Hu, G; Liu, J; Ran, X; Wang, H; Yang, Y; Yang, Z | 1 |
| Aird, KM; Devi, GR; Ghanayem, RB; Lyerly, HK; Peplinski, S | 1 |
| Crane, K | 1 |
3 other study(ies) available for quinazolines and Mastitis
| Article | Year |
|---|---|
Evodiamine Relieve LPS-Induced Mastitis by Inhibiting AKT/NF-κB p65 and MAPK Signaling Pathways.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Female; Lipopolysaccharides; Mastitis; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; NF-kappa B; Proto-Oncogene Proteins c-akt; Quinazolines; Random Allocation; Signal Transduction; Transcription Factor RelA | 2022 |
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Breast Neoplasms; Carcinoma; Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Mastitis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sulfones; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |